Biofocus DPI has announced that it has enhanced its high-content screening capabilities through the implementation of precision liquid handling instruments and advanced cell imaging devices.
As part of Biofocus DPI's Intelligent Screening platform, high-content screening is paired with the use of disease-relevant assays in human primary cells to provide detailed information on the effect proteins and small molecules have on a disease phenotype.
The technique is particularly useful for small molecule mechanism-of-action studies and disease pathway analyses used in target discovery campaigns.
With a newly acquired Caliper Zephyr liquid handling instrument and wide-field (Incell1000) and confocal (BD Pathway) imaging devices, Biofocus DPI has increased both the throughput and quality of its high-content screening and imaging capabilities.
This enables Biofocus DPI to further develop customised, biologically relevant assays for partners' discovery programmes.
Biofocus DPI customers utilising Primepath (compound screening service that uses disease-relevant assays in human primary cells) and its proprietary adenoviral shRNA target discovery platform will benefit from Biofocus DPI's expertise within a range of target classes and disease areas.
